Regeneration Biomedical's Phase I trial shows stem cell therapy reduces Alzheimer's Disease biomarkers and improves cognition.
Read more
Eli Lilly's modified donanemab dosing reduces ARIA-E incidence by 41% in early symptomatic Alzheimer's Disease patients in Phase 3b study.
Read more
Zai Lab's Phase 3 trial in China shows KarXT significantly reduces symptoms of Schizophrenia, paving way for NDA submission.
Read more
Immunovant to present Phase 2 trial data on batoclimab for Graves' Disease at 2024 ATA Annual Meeting.
Read more
Plus Therapeutics presents Phase 1 trial results for Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases at 2024 SNO Annual Meeting.
Read more
Delta-Fly Pharma's Phase I/II trial of DFP-10917 and Venetoclax shows promising initial results in Acute Myeloid Leukemia patients.
Read more
Monte Rosa Therapeutics partners with Novartis to advance VAV1-directed molecular glue degraders, receiving $150 million upfront and potential $2.1 billion in milestone payments.
Read more
UroGen's UGN-102 shows 82.3% 12-month response duration in Phase 3 trial for low-grade intermediate-risk non-muscle-invasive bladder cancer, with FDA review set for June 2025.
Read more
Biogen and Neomorph partner to develop molecular glue degraders targeting Alzheimer's Disease, rare neurological, and immunological diseases.
Read more
Medable partners with Google Cloud to offer its Digital Clinical Trial Platform on Google Cloud Marketplace, enhancing trial design and management with AI capabilities.
Read more
Biond Biologics partners with Merck KGaA to evaluate BND-35 and cetuximab in Phase 1 trial for solid tumors.
Read more
FDA accepts BLA for HLX14, a biosimilar to denosumab, for osteoporosis treatment in postmenopausal women.
Read more
Scilex Pharmaceuticals advances SP-103 for Chronic Neck Pain to Phase III trials after successful FDA meeting.
Read more
Allogene Therapeutics' ALLO-316 receives FDA RMAT designation for advanced Renal Cell Carcinoma, following positive TRAVERSE trial data.
Read more
Purdue Pharma study shows nalmefene effectively reverses fentanyl-induced respiratory depression, offering a longer-acting alternative to naloxone in opioid overdose treatment.
Read more
T-Neuro Pharma expands Alzheimer's Disease blood biomarker assay to include HLA-A2-negative patients, enhancing diagnostic reach.
Read more
Nexalin Technology's study shows Deep Intracranial Frequency Stimulation improves cognitive function in Alzheimer's Disease patients, offering a non-invasive treatment option.
Read more
Pathos AI secures $62M in Series C funding to enhance its AI-driven drug development platform for precision oncology.
Read more
FDA accepts PTC Therapeutics' NDA resubmission for Translarna, targeting nonsense mutation Duchenne Muscular Dystrophy.
Read more
Kivu Bioscience raises $92 million to advance next-generation antibody-drug conjugates for oncology, targeting improved safety and efficacy.
Read more
Biora Therapeutics advances BioJetā¢ device, offering largest payload for oral delivery, aiming for Q4 2024 testing completion.
Read more
ImmunoPrecise Antibodies collaborates with Mayo Clinic to advance anti-aging research, developing antibodies to monitor mitochondrial health, crucial for neurodegenerative diseases like Parkinson's Disease and Alzheimer's Disease.
Read more
RiboX Therapeutics receives FDA clearance for RXRG001, the first circular RNA therapy for Radiation-Induced Xerostomia and Hyposalivation.
Read more
AbbVie acquires Aliada Therapeutics for $1.4 billion, enhancing its Alzheimer's Disease pipeline with ALIA-1758 and novel blood-brain barrier technology.
Read more
Ajax Therapeutics begins Phase 1 trial of AJ1-11095, a novel Type II JAK2 inhibitor, for Myelofibrosis treatment.
Read more
